Eli Lilly and Co. (NYSE:LLY) shares are trading lower Wednesday, pulling back after the stock notched an all-time high just last week, even as the company separately reported positive real-world data on its weight-loss drug Zepbound. Here’s what you should know.
- Eli Lilly stock is showing notable weakness. What’s behind LLY decline?
Eli Lilly Pulls Back After Hitting Record Highs Last Week
Eli Lilly shares touched an all-time intraday high of $1,292.65 and closed at a record $1,280.34 on Aug. 19, before easing off those levels in the sessions since. Shares have traded in a range of $1,180.01 to $1,235.775 more recently, still well within the stock’s 52-week range of $694.23 to $1,292.65, according to Benzinga Pro.
The pullback looks like a normal consolidation after a strong run to fresh highs rather than a reaction to any specific negative news.
New Study Shows Zepbound Lowering Healthcare Costs in Older Adults
Separately, Eli Lilly rolled out findings from a new real-world analysis focused on older adults carrying excess weight, showing that people who kept taking Zepbound saw their overall healthcare spending come down compared with similar patients who went untreated, a gap the company attributed mainly to fewer trips to the hospital and emergency room. Lilly said no prior research had examined this specific age bracket in this way, and the findings were published in the academic journal Diabetes, Obesity and Metabolism.
Looking at the actual numbers, patients who continued on Zepbound saw monthly costs come in up to 15% lower after half a year, translating to roughly $181 in savings per patient each month. That advantage grew even larger by the one-year mark, reaching an estimated $607 in monthly per-patient savings, or about 38% below what untreated patients spent, based on the study’s main statistical approach.
Beyond the dollar figures, patients over 55 taking the drug consistently visited hospitals and emergency rooms less often no matter how long researchers tracked them, while showing up more frequently for routine checkups and office visits, a pattern the study’s authors linked to patients staying more engaged with regular preventive care.
Those savings started adding up fast: within six months, the reduction in other healthcare costs had come close to canceling out the $195 monthly price tag for treatment under Medicare’s GLP-1 Bridge program, and by the one-year mark, the savings had actually surpassed what patients spent on the drug itself.
LLY Shares Are Falling
LLY Price Action: Eli Lilly shares were down 3.17% at $1194.57 at the time of publication on Wednesday, according to Benzinga Pro.
Image: Shutterstock
Login to comment